Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares

Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics, Matsuda, divested 3,674 shares of the company's common stock on September 16, 2026. The shares were traded at prices between $25.00 and $25.01, resulting in a sale worth approximately $91,853. This sale occurred while ARQT stock has experienced a 49% return over the past year.

However, the stock is currently valued below its InvestingPro Fair Value, indicating potential undervaluation. Despite this, Arcutis Biotherapeutics has turned profitable over the last year, boasting impressive gross profit margins of 91%. Matsuda, who now owns 112,508 shares of the company's common stock, executed the sale under a pre-arranged 10b5-1 trading plan that was adopted on June 5, 2026, and is set to end on September 1, 2027.

Arcutis Biotherapeutics reported a significant jump in revenue for the second quarter of 2026, reaching $129.9 million. This marked an increase of 59% compared to forecasts and 23% year-over-year growth. The company's revenue exceeded market expectations of $118.47 million and Guggenheim's estimate of $117.5 million, indicating strong growth driven by rising demand and improved pricing strategies.

Following these results, Guggenheim raised its price target for the company from $35 to $38, maintaining a Buy rating, citing the robust sales of Zoryve as the key reason for its decision.